IFT Annual Meeting & Food Expo In Brief

Cantox expert advises on claim support: FDA's "competent and reliable scientific evidence" standard for structure/function claims appears less rigorous than its "significant scientific agreement" requirement for authorized or qualified disease-risk reduction claims, but is not actually so, regulatory consultant Kathy Musa-Veloso says. "Don't be deceived by this competent and reliable scientific evidence standard," she said July 19 at the Institute of Food Technologists Annual Meeting & Food Expo in Chicago. "In our view, it's really just a synonym for significant scientific agreement." Musa-Veloso, associate director of Cantox's Food & Nutrition Group, said even though industry stakeholders are surprised at the European Food Safety Authority's rejection rate for proposed nutrient claims, most structure/function claims in the U.S. likewise would be rejected (1"The Tan Sheet" June 7, 2010). FDA does not require firms to submit their products' structure/function claims for approval and clearly some product claims on the market are not substantiated. "If the food industry wants to encapsulate bioactives and claim efficacy akin to pharmaceuticals, [regulators] are expecting the same level of scientific data - robust clinical studies - which for the most part, do not exist," Musa-Veloso added during a session on health claims

More from Archive

Ocaliva: Still No Clarity On Why EU Court Opposed Revocation Of Approval

 

Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.

Brazil Pilots Digital Drug Pack Inserts

 

A new pilot aims to take Brazil closer to ‘digital transformation.’

More from Pink Sheet

New Measures Can Cut Israel’s Drug Approval Time To Just 70 Days

 

Israel has introduced a new framework to expedite the marketing approval of medicines, make the country a more attractive destination for drug registration and help reduce drug prices through market competition.

Global Pharma Guidance Tracker March 2025

 

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By 

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth